<p>Novartis AG reported fourth quarter (Q4) net sales of USD 13.34 billion, reflecting a 1 percent increase. Operating income for the period reached USD 3.62 billion, up 2 percent. Net income for the quarter was USD 2.40 billion, with earnings per share (EPS) at USD 1.26. For the full year (FY) 2025, Novartis AG posted net sales of USD 54.53 billion, up 8 percent. Operating income for the year was USD 17.64 billion, an increase of 21 percent. Net income rose to USD 13.97 billion, representing a 17 percent increase, and EPS was USD 7.21, up 22 percent. Novartis AG highlighted strategic pipeline developments during the period, including the proposed acquisition of Avidity, which is expected to close in the first half of the year. The company noted it remains focused on four core therapeutic areas: cardiovascular-renal-metabolic, immunology, neuroscience, and oncology, while prioritizing investments in emerging technology platforms such as gene and cell therapy, radioligand therapy, and xRNA. The company confirmed it achieved its 2025 Patient Access Targets under its sustainability-linked bond, resulting in no interest rate adjustment for the bond, which will continue to pay zero percent interest until its maturity in September 2028. As of Q4 2025, Novartis AG’s long-term credit rating stands at Aa3 with Moody’s Ratings and AA- with S&amp;P Global Ratings. Looking ahead to 2026, Novartis AG expects net sales to grow in the low single-digit range, while core operating income is anticipated to decline in the low single-digit range, barring unforeseen events. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novartis AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001162862-en) on February 04, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)</p>

IBBQ

Reuters

iShares Biotechnology ETF

VG Health

Invesco Nasdaq Biotechnology ETF

Novartis AG

Invesco Biotechnology & Genome ETF

NOVARTIS AG

Ark Genomic Revolution ETF

ALPS Medical Breakthrough

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

Health Care Select Sector SPDR

iShares US Pharma

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

Novartis Q4 FY25 operating income rises to USD 3.62 billion, up 21%